Abstract:Introduction: Bupropion toxicity can cause cardiogenic shock, ventricular dysrhythmias, and death. Clinical and electrocardiographic factors associated with adverse cardiovascular events in bupropion toxicity have not been well-studied. This study aimed to identify factors associated with adverse cardiovascular events in adult patients with isolated bupropion exposures. Methods: This retrospective cohort study queried the National Poison Data System from 2019 through 2020. We included patients 20 years or older with acute or acute-on-chronic single-agent bupropion exposures evaluated in a healthcare facility. Exclusion criteria were confirmed non-exposure, withdrawal as a reason for exposure, lack of follow-up, documentation that exposure was probably not responsible for the effects, and missing data. The primary outcome was adverse cardiovascular events, defined as the presence of any of the following: vasopressor use, ventricular dysrhythmia, myocardial injury, or cardiac arrest. Independent variables were age, the intentionality of exposure, seizures, tachycardia, QRS widening, and QTc prolongation. Multivariable logistic regression was performed to test for independent associations between independent variables and adverse cardiovascular events. Results: Of 4,640 patients included in the final analysis (56.7% female, 56.5% suspected suicidal intent), 68 (1.47%) experienced an adverse cardiovascular event. Age (odds ratio 1.03; 95% confidence intervals 1.02-1.05), single seizure (odds ratio 9.18; 95% confidence intervals 4.24-19.9) and complicated seizures (odds ratio 38.9; 95% confidence intervals 19.3-78.1), QRS widening (odds ratio 3.01; 95% confidence intervals 1.62-5.59), and QTc prolongation (odds ratio 1.76; 95% confidence intervals 1.00-3.10) were independently associated with adverse cardiovascular events. No patients with unintentional exposure experienced adverse cardiovascular events, prohibiting intentionality from inclusion in the regression model. In the post hoc subgroup analysis of intentional exposures, age, single and complicated seizures, and QRS widening remained independently associated with adverse cardiovascular events. Conclusions: Increasing age, seizures, QRS widening, and QTc prolongation were associated with adverse cardiovascular events in bupropion exposures. Adverse cardiovascular events did not occur in unintentional exposures. Further research is needed to develop screening tools and treatments for bupropion cardiotoxicity.

Gap junction modulators: Prospects in bupropion cardiotoxicity

Carvedilol and Its New Analogs Suppress Arrhythmogenic Store Overload–induced Ca2+ Release

Cardiovascular Collapse Requiring Veno-Arterial Extracorporeal Membrane Oxygenation and Lidocaine: A Case of Massive Bupropion Overdose

Abstract 15659: Bupropion Overdose Requiring Veno-Arterial Extracorporeal Membrane Oxygenation

Bupropion: Does Its Efficacy Outweigh Potential Morbidity and Lethality?

Clinical and electrocardiographic factors associated with adverse cardiovascular events in bupropion exposures

Abstract 17489: Bupropion Poisoning: Extracorporeal Membrane Oxygenation as a Rescue Strategy

Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: Animal and human studies

Treatment of status epilepticus and prolonged QT after massive intentional bupropion overdose with lidocaine

Predicting adverse cardiovascular events in emergency department patients with bupropion overdose

Cardiotoxicity of Current Antipsychotics: Newer Antipsychotics or Adjunct Therapy?

Proarrhythmic effects induced by benzethonium chloride and domiphen bromide in vitro and in vivo

[Gap junctions: A new therapeutic target in major depressive disorder?]

Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity

Gain of function mutants reveal sites important for the interaction of the atypical inhibitors benztropine and bupropion with monoamine transporters

Potential cardioprotective influence of bupropion against CCl4-triggered cirrhotic cardiomyopathy

Interrelated In Vitro Mechanisms of Sibutramine-Induced Cardiotoxicity

Biased Β2‐adrenoceptor Signalling in Heart Failure: Pathophysiology and Drug Discovery

Characterization of loperamide-mediated block of hERG channels at physiological temperature and its proarrhythmia propensity

Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation

Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future